Prebiotic‐Based Nanoamorphous Atorvastatin Attenuates Nonalcoholic Fatty Liver Disease by Retrieving Gut and Liver Health
Source abstract
Abstract
Nonalcoholic Fatty Liver Disease In article 2200312, Jian-Dong Jiang, Yongsheng Che, Lu-Lu Wang, and co-workers developed a prebiotic-based nano-amorphous form of atorvastatin with the aim of improving nonalcoholic fatty liver disease. The innovative approach targets both liver and gut health, making it a promising strategy for treating metabolic diseases and maintaining homeostasis in both the host and symbiotic bacterial systems.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Liver Disease Diagnosis and Treatment · Gut microbiota and health · Metabolomics and Mass Spectrometry Studies
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Institute of Medicinal Biotechnology Chinese Academy of Medical Science and Peking Union Medical College Beijing 100050 China
Institute of Materia Medica Chinese Academy of Medical Science and Peking Union Medical College Beijing 100050 China
State Key Laboratory of Phytochemistry and Plant Resource in West China Kunming Institute of Botany Chinese Academy of Sciences Kunming 650201 China
References
Reference metadata was not supplied for this record.